(NASDAQ: CLGN) Collplant Biotechnologies's forecast annual revenue growth rate of 133.47% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 283.85%, and while it is forecast to beat the US market's average forecast revenue growth rate of 58.14%.
Collplant Biotechnologies's revenue in 2025 is $2,402,000.On average, 4 Wall Street analysts forecast CLGN's revenue for 2025 to be $101,303,704, with the lowest CLGN revenue forecast at $51,636,940, and the highest CLGN revenue forecast at $153,238,462. On average, 4 Wall Street analysts forecast CLGN's revenue for 2026 to be $185,929,639, with the lowest CLGN revenue forecast at $155,208,638, and the highest CLGN revenue forecast at $216,490,277.
In 2027, CLGN is forecast to generate $162,676,979 in revenue, with the lowest revenue forecast at $95,416,085 and the highest revenue forecast at $232,686,957.